Loading...
XSHE
300871
Market cap640mUSD
Oct 09, Last price  
20.91CNY
1D
-1.60%
1Q
-7.52%
IPO
-60.04%
Name

Wuhan Hvsen Biotechnology Co Ltd

Chart & performance

D1W1MN
XSHE:300871 chart
P/E
16.67
P/S
2.51
EPS
1.25
Div yield, %
0.97%
Shrs. gr., 5y
4.07%
Rev. gr., 5y
11.03%
Revenues
1.68b
+40.07%
257,783,399399,715,931421,874,231427,217,125777,458,548996,216,817996,216,8161,022,900,7921,022,900,7911,019,758,7981,200,327,9321,681,248,059
Net income
253m
P
49,441,50088,424,28871,401,57768,766,358150,156,116132,865,534132,865,53652,706,47552,706,47816,780,822-20,155,586253,155,975
CFO
238m
+447.76%
60,004,00080,558,56221,095,638105,241,48248,349,261155,718,48996,680,49092,919,34343,531,846238,448,397
Dividend
Sep 08, 20260.3 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Hvsen Biotechnology Co., Ltd. is a company based in Wuhan, China, that focuses on the global research, development, and manufacturing of macrolide active pharmaceutical ingredients (APIs) and finished drug products. The company's diverse product portfolio features tylvalosin, offered in both raw material form and various preparations, along with florfenicol preparations and a broader selection of other macrolide-based offerings. Additionally, Hvsen produces a range of veterinary pharmaceuticals, available as both raw ingredients and finished drugs, alongside traditional Chinese medicine extracts.

Key people

Jie Han
General Manager · since 2025
Jinbin Huang
Deputy General Manager · since 2020
Shuo Li
Deputy General Manager · since 2022
Yanshu Wu
Deputy General Manager
Kaijie Yang
Chief Financial Officer, Deputy General Manager · since 2024
Qingfeng Wang
Secretary of the Board · since 2022
Zexiang Liu
Director · since 2022
Weiyuan Zhang
Chairman of the Board · since 2023
Jian Zhou
Staff Elected Director · since 2025
Mingdong Ran
Independent Director · since 2024
Ming Wang
Independent Director · since 2025
IPO date
Aug 24, 2020
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122022‑002021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT